NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
27 juil. 2021 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Strengthens Management Team with Key Appointments
14 juil. 2021 16h01 HE
|
NexImmune, Inc.
Dr. Jack A. Ragheb as Senior Vice President, Translational ScienceMatt Schiller, Head of Business Development GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a...
NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference
16 juin 2021 16h29 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Formation of Scientific Advisory Board
27 mai 2021 08h00 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting
19 mai 2021 16h21 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
17 mai 2021 16h01 HE
|
NexImmune, Inc.
Advancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public offering (IPO) in February 2021 Additional clinical and preclinical data anticipated in the...
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
21 avr. 2021 07h30 HE
|
NexImmune, Inc.
Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a...
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
31 mars 2021 16h54 HE
|
NexImmune, Inc.
In 2020, advanced two product candidates into Phase 1/2 clinical trials while strengthening Board of Directors and management teamCompleted successful $126M initial public offering (IPO) in February...
NexImmune to Present at the 2021 Barclays Global Healthcare Conference
02 mars 2021 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17 févr. 2021 18h34 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s...